- The World Health Organization held a media briefing on 17 June, to update the public on the COVID-19 coronavirus pandemic.
- Caution was urged following initial promising results in a UK drug trial.
- Dexamethasone has been shown to reduce mortality in the most critically ill patients.
The WHO welcomes initial promising results from the UK RECOVERY trial into the use of dexamethasone in treating COVID-19, said Director-General Dr Tedros Adhanom Ghebreyesus. But, the organization also urged caution in use of the drug.
Have you read?
The drug - a steriod - was shown to be effective in treating the most serious cases. It reduces mortality by around a fifth for patients receiving oxygen alone, and by around a third for patients requiring a ventilator, Dr Tedros explained.
Proceed with caution
Dr Michael Ryan, Executive Director of the WHO's Health Emergencies Programme, also welcomed the results. "It's great news," he said. "But, it's part of the answer on the clinical side."
He also cautioned that it's vital the drug is only used under medical supervision and not as a preventative measure. "It is not a treatment for the virus itself," he explained. It's important its use is reserved for severely ill patients.
What is the World Economic Forum doing to manage emerging risks from COVID-19?
The first global pandemic in more than 100 years, COVID-19 has spread throughout the world at an unprecedented speed. At the time of writing, 4.5 million cases have been confirmed and more than 300,000 people have died due to the virus.
As countries seek to recover, some of the more long-term economic, business, environmental, societal and technological challenges and opportunities are just beginning to become visible.
To help all stakeholders – communities, governments, businesses and individuals understand the emerging risks and follow-on effects generated by the impact of the coronavirus pandemic, the World Economic Forum, in collaboration with Marsh and McLennan and Zurich Insurance Group, has launched its COVID-19 Risks Outlook: A Preliminary Mapping and its Implications - a companion for decision-makers, building on the Forum’s annual Global Risks Report.
Companies are invited to join the Forum’s work to help manage the identified emerging risks of COVID-19 across industries to shape a better future. Read the full COVID-19 Risks Outlook: A Preliminary Mapping and its Implications report here, and our impact story with further information.
His message was echoed by Dr Janet Diaz, Head of Clinical Care, who reiterated the message that the drug was not shown to have an effect on patients with mild cases.
Equally, we musn't rush to update the clinical advice - appropriate doses, how people are assessed, training for example - urged Dr Ryan. "We still need to see the data, we need to adjust the clinical guidelines that will be needed and we need to support countries to both access and utilize this drug in the most appropriate way possible."
It's significant, but it's still just preliminary data from one study, he said.
Don't forget other diseases
Dr Tedros also emphasized that COVID-19 is just one of the threats that the world's most vulnerable communities face and called for essential services to continue.
"COVID-19 has wreaked havoc in the world, and one of the things that has been severely affected is our neglected tropical disease programmes worldwide," explained Dr Mwelecele Ntuli Malecela, Director, Department of Control of Neglected Tropical Diseases.
The impact has been particularly strong in Africa, with mass drug administration programmes stopped across the continent. The organization is looking to the future - how to carry out these programmes more effectively and to ensure the safety of all involved, she added.